DeepMed Research

Incyte

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 2.5K

Market Cap: $12.6B

Website

Introduction: Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

Clinical Trials

To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma

Phase 1

Completed

Conditions: Myelodysplastic Syndromes
Anemia
Multiple Myeloma

Interventions: Drug: INCB000928

First Posted Date: 2020-10-09

Last Posted Date: 2024-08-29

Lead Sponsor: Incyte Corporation

Target Recruit Count: 22

Registration Number: NCT04582539

Locations: 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸
Barbara Ann Karmanos Cancer Hospital, Detroit, Michigan, United States

and more 12 locations

INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

Phase 1

Completed

Conditions: Non Small Cell Lung Cancer
Castration Resistant Prostate Cancer
Colorectal Cancer
Triple Negative Breast Cancer
Gastric/ Gastroesophageal Junction
Squamous Carcinoma of the Anal Canal
Squamous Cell Carcinoma of Head and Neck
Pancreatic Ductal Adenocarcinoma
Ovarian Cancer
Bladder Cancer

Interventions: Drug: INCB106385
Drug: INCMGA00012

First Posted Date: 2020-10-08

Last Posted Date: 2025-02-18

Lead Sponsor: Incyte Corporation

Target Recruit Count: 54

Registration Number: NCT04580485

Locations: 🇧🇪
Cliniques Universitaires Ucl Saint-Luc, Brussels, Belgium
🇺🇸
Cedars-Sinai Medical Center, West Hollywood, California, United States
🇺🇸
University of Maryland-Greenebaum Cancer Center, Baltimore, Maryland, United States

and more 24 locations

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

Phase 3

Terminated

Conditions: Myelofibrosis
Post Polycythemia Vera Myelofibrosis
Primary Myelofibrosis
Post Essential Thrombocythemia Myelofibrosis

Interventions: Drug: parsaclisib
Drug: placebo
Drug: ruxolitinib

First Posted Date: 2020-09-16

Last Posted Date: 2024-12-19

Lead Sponsor: Incyte Corporation

Target Recruit Count: 252

Registration Number: NCT04551066

Locations: 🇺🇸
Kelsey Seybold Clinic, Houston, Texas, United States
🇧🇪
A.Z. St.-Jan A.V., Brugge, Belgium
🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

and more 172 locations

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Phase 3

Terminated

Conditions: Myelofibrosis
Post Polycythemia Vera Myelofibrosis
Primary Myelofibrosis
Post Essential Thrombocythemia Myelofibrosis

Interventions: Drug: parsaclisib
Drug: placebo
Drug: ruxolitinib

First Posted Date: 2020-09-16

Last Posted Date: 2024-08-23

Lead Sponsor: Incyte Corporation

Target Recruit Count: 177

Registration Number: NCT04551053

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States

and more 167 locations

Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo

Phase 3

Completed

Conditions: Vitiligo

Interventions: Drug: ruxolitinib
Drug: Vehicle

First Posted Date: 2020-08-28

Last Posted Date: 2023-07-19

Lead Sponsor: Incyte Corporation

Target Recruit Count: 458

Registration Number: NCT04530344

Locations: 🇺🇸
First Oc Dermatology, Fountain Valley, California, United States
🇺🇸
Dermatology Research Associates, Los Angeles, California, United States
🇺🇸
Advanced Pharma, Miami, Florida, United States

and more 81 locations

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Phase 2

Active, not recruiting

Conditions: B-Cell Malignancies

Interventions: Drug: Parsaclisib
Drug: parsaclisib + itacitinib
Drug: parsaclisib + ibrutinib
Drug: parsaclisib + ruxolitinib

First Posted Date: 2020-08-12

Last Posted Date: 2025-04-22

Lead Sponsor: Incyte Corporation

Target Recruit Count: 112

Registration Number: NCT04509700

Locations: 🇺🇸
Uab Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸
University of Alabama At Birmingham, Birmingham, Alabama, United States
🇺🇸
Mayo Clinic Rochester, Phoenix, Arizona, United States

and more 101 locations

To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa

Phase 2

Completed

Conditions: Hidradenitis Suppurativa
Acne Inversa

Interventions: Drug: INCB054707
Drug: Placebo

First Posted Date: 2020-07-17

Last Posted Date: 2023-09-28

Lead Sponsor: Incyte Corporation

Target Recruit Count: 209

Registration Number: NCT04476043

Locations: 🇺🇸
Investigative Site 018, Bellaire, Texas, United States
🇩🇪
Investigative Site 403, Berlin, Germany
🇩🇪
Investigative Site 401, Bochum, Germany

and more 37 locations

Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

Phase 3

Active, not recruiting

Conditions: Squamous Cell Carcinoma of the Anal Canal

Interventions: Drug: carboplatin
Drug: paclitaxel
Drug: retifanlimab

First Posted Date: 2020-07-15

Last Posted Date: 2024-12-20

Lead Sponsor: Incyte Corporation

Target Recruit Count: 308

Registration Number: NCT04472429

Locations: 🇺🇸
Sansum Clinic, Santa Barbara, California, United States
🇫🇷
Chu Besancon Hospital Jean Minjoz, Besançon, France
🇺🇸
Texas Oncology-Wichita Falls Texoma Cancer Center, Wichita Falls, Texas, United States

and more 80 locations

Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

Phase 2

Active, not recruiting

Conditions: Endometrial Cancer

Interventions: Drug: retifanlimab
Drug: INCAGN02385
Drug: epacadostat
Drug: INCAGN02390
Drug: pemigatinib

First Posted Date: 2020-07-09

Last Posted Date: 2025-04-24

Lead Sponsor: Incyte Corporation

Target Recruit Count: 300

Registration Number: NCT04463771

Locations: 🇺🇸
Advent Health Medical Group-Orlando 2501, Orlando, Florida, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute Hospital, Tampa, Florida, United States
🇺🇸
Alaska Womens Cancer Care Akwcc, Anchorage, Alaska, United States

and more 62 locations

INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

Phase 1

Active, not recruiting

Conditions: Post-essential Thrombocythemia Myelofibrosis
Post-polycythemia Vera Myelofibrosis
Anemia

Interventions: Drug: INCB000928
Drug: ruxolitinib

First Posted Date: 2020-07-02

Last Posted Date: 2025-05-04

Lead Sponsor: Incyte Corporation

Target Recruit Count: 84

Registration Number: NCT04455841

Locations: 🇺🇸
Start Midwest, Grand Rapids, Michigan, United States
🇺🇸
Emory University-Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States

and more 31 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy